Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating restated by stock analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They presently have a $190.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 2.71% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $247.00 to $233.00 in a research note on Wednesday, July 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $240.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 25th. Finally, Chardan Capital reiterated a “buy” rating and issued a $250.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, August 8th. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $247.40.

Alnylam Pharmaceuticals Trading Down 4.2 %

ALNY stock opened at $184.99 on Thursday. The firm’s 50-day moving average price is $194.45 and its two-hundred day moving average price is $195.57. Alnylam Pharmaceuticals has a 12-month low of $178.64 and a 12-month high of $242.97. The stock has a market capitalization of $23.12 billion, a price-to-earnings ratio of -21.49 and a beta of 0.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.49). The company had revenue of $318.75 million for the quarter, compared to the consensus estimate of $331.73 million. Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative return on equity of 1,287.80%. Equities analysts predict that Alnylam Pharmaceuticals will post -6.79 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 4,166 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $183.89, for a total value of $766,085.74. Following the completion of the transaction, the chief marketing officer now directly owns 4,345 shares in the company, valued at $799,002.05. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Yvonne Greenstreet sold 4,057 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $185.85, for a total transaction of $753,993.45. Following the completion of the transaction, the chief executive officer now owns 35,216 shares in the company, valued at $6,544,893.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 4,166 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $183.89, for a total transaction of $766,085.74. Following the transaction, the chief marketing officer now owns 4,345 shares of the company’s stock, valued at approximately $799,002.05. The disclosure for this sale can be found here. Insiders sold a total of 15,144 shares of company stock worth $2,806,347 over the last three months. 1.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Belpointe Asset Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $25,000. Capital Advisors Ltd. LLC boosted its position in shares of Alnylam Pharmaceuticals by 1,480.0% during the second quarter. Capital Advisors Ltd. LLC now owns 158 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 148 shares during the last quarter. KB Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $35,000. Archer Investment Corp bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $40,000. Finally, V Square Quantitative Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $53,000. Institutional investors own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.